Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity (2023 - 2026)

Contineum Therapeutics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $261.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 31.82% year-over-year to $261.3 million; the TTM figure through Mar 2026 stood at $911.7 million (up 7.45% YoY), while the FY2025 annual figure was $276.6 million, up 29.97% from the prior year.
• Liabilities and Shareholders Equity was $261.3 million for Q1 2026 at Contineum Therapeutics, down from $276.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $276.6 million in Q4 2025 to a low of $123.6 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $201.4 million across 4 years, with a median of $205.6 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 63.24% in 2024, then dropped 17.38% in 2025.
• A 4-year view of Liabilities and Shareholders Equity shows it stood at $130.4 million in 2023, then soared by 63.24% to $212.8 million in 2024, then increased by 29.97% to $276.6 million in 2025, then dropped by 5.53% to $261.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $261.3 million (Q1 2026), $276.6 million (Q4 2025), and $190.8 million (Q3 2025), per Business Quant data.